Determining the Optimal Ceftriaxone MIC for Triggering Extended-Spectrum  -Lactamase Confirmatory Testing

Treatment of Multidrug-Resistant Gram-Negative Infections in Children

(2014) A. J. Hsu et al.   CLINICAL INFECTIOUS DISEASES

Do Patient Data Really Support the Clinical and Laboratory Standards Institute Recommendation for Lowering Third-Generation Cephalosporin Interpretive Breakpoints?

(2013) P. D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae

(2013) Pranita D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam

(2013) Michael N. Dudley et al.   CLINICAL INFECTIOUS DISEASES

Outcomes of Children With Enterobacteriaceae Bacteremia With Reduced Susceptibility to Ceftriaxone

(2013) Pranita D. Tamma et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae: MIC Matters

(2012) Nan-Yao Lee et al.   CLINICAL INFECTIOUS DISEASES

Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests

(2012) Dror Marchaim et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

An Outbreak of Extended-Spectrum β-Lactamase–Producing Klebsiella pneumoniae in a Neonatal Intensive Care Unit

(2012) Pranita D. Tamma et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Can We Really Use ss-Lactam/ss-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ss-Lactamase-Producing Bacteria?

(2011) F. Perez et al.   CLINICAL INFECTIOUS DISEASES